Meta-Analysis of Randomized Controlled Trial in Treating Primary Liver Cancer by Fufang Kushen Injection Combined with TACE
- DOI
- 10.2991/icseee-15.2016.142How to use a DOI?
- Keywords
- Fufang Kushen Injection, TACE, Primary Liver Cancer, Meta analysis
- Abstract
Objective. To evaluate effectiveness and safety of Fufang Kushen Injection combined with transcatheter arterial chemoembolization (TACE) for primary liver cancer (PLC). Search Strategy. Electronic databases were searched until 2 July, 2015. Inclusion Criteria. We included randomized clinical trials about comparison between Fufang Kushen Injection combined with TACE (FFKS-TACE) and TACE alone for treatment of PLC. Data Extraction and Analyses. Study selection, data extraction, quality assessment, and data analyses were conducted according to Cochrane standards. Results. 19 randomized trials were included. Methodological quality of the included trials was evaluated as generally low. compared with TACE alone, Meta-analysis showed that FFKS-TACE significantly improved the effective rate, KPS, six-month, one-year and two-year survival; significantly reduced the incidence of nausea and vomiting, fever, myelosuppression, transminase increased, bilirubin increased and stomach ache. Conclusion. FFKS-TACE for PLC can not only improve the effectiveness rate, KPS and survival rate, but also reduce the incidence rate of the clinical adverse effects such as nausea and vomiting, fever, myelosuppression, hepatic injury and stomach ache. However, the conclusion needs to be proved by further experiments on account of the absence of high quality articles. But evidence remains weak, rigorously designed trials are warranted to confirm these results.
- Copyright
- © 2016, the Authors. Published by Atlantis Press.
- Open Access
- This is an open access article distributed under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).
Cite this article
TY - CONF AU - Dehui Li AU - Huanfang Fan AU - Chunxia Sun PY - 2016/04 DA - 2016/04 TI - Meta-Analysis of Randomized Controlled Trial in Treating Primary Liver Cancer by Fufang Kushen Injection Combined with TACE BT - Proceedings of the 2015 4th International Conference on Sustainable Energy and Environmental Engineering PB - Atlantis Press SP - 817 EP - 821 SN - 2352-5401 UR - https://doi.org/10.2991/icseee-15.2016.142 DO - 10.2991/icseee-15.2016.142 ID - Li2016/04 ER -